Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/203640
Title: | Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration |
Author: | Díaz González, Álvaro Hernández Guerra, Manuel Pérez Medrano, Indhira Sapena, Víctor Riveiro Barciela, Mar Barreira Díaz, Ana Gómez, Elena Morillas, Rosa M. Barrio, María del Escudé, Laia Mateos, Beatriz Horta, Diana Gómez, Judith Conde, Isabel Ferre Aracil, Carlos El Hajra, Ismael Arencibía, Ana Zamora, Javier Fernández, Ainhoa Salcedo, Magdalena Molina, Esther Soria, Anna Estévez, Pamela López, Carmen Álvarez Navascués, Carmen García Retortillo, Montserrat Crespo, Javier Londoño, María Carlota ColHai Registry |
Keywords: | Hepatitis Malalties autoimmunitàries Corticosteroides Hepatitis Autoimmune diseases Adrenocortical hormones |
Issue Date: | 1-Apr-2023 |
Publisher: | Wolters Kluwer Health, Inc. |
Abstract: | In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options.This was a retrospective, multicenter study of 105 naive AIH patients treated with budesonide as the first-line drug. The control group included 276 patients treated with prednisone. Efficacy was assessed using logistic regression and validated using inverse probability of treatment weighting propensity score. The median time to biochemical response (BR) was 3.1 months in patients treated with budesonide and 4.9 months in those with prednisone. The BR rate was significantly higher in patients treated with prednisone (87% vs. 49% of patients with budesonide, p < 0.001). The probability of achieving BR, assessed using the inverse probability of treatment weighting propensity score, was significantly lower in the budesonide group (OR = 0.20; 95% CI: 0.11-0.38) at any time during follow-up, and at 6 (OR = 0.51; 95% CI: 0.29-0.89) and 12 months after starting treatment (0.41; 95% CI: 0.23-0.73). In patients with transaminases <2 × upper limit of normal, BR was similar in both treatment groups. Prednisone treatment was significantly associated with a higher risk of adverse events (24.2% vs. 15.9%, p = 0.047).In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.Copyright © 2023 American Association for the Study of Liver Diseases. |
Note: | Reproducció del document publicat a: https://doi.org/10.1097/hep.0000000000000018 |
It is part of: | Hepatology, 2023, vol. 77, num. 4, p. 1095-1105 |
URI: | http://hdl.handle.net/2445/203640 |
Related resource: | https://doi.org/10.1097/hep.0000000000000018 |
ISSN: | 1527-3350 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
HEP-22-0918.R2_Proof_hi.pdf | 1.12 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.